Zepbound vs Wegovy: Tirzepatide vs Semaglutide for Weight Loss

Zepbound and Wegovy are the two major branded weight-loss injections people compare. Zepbound contains tirzepatide. Wegovy contains semaglutide.

The short answer: Zepbound generally wins on average weight loss. Wegovy still has important label strengths, including cardiovascular risk-reduction use in a defined population, and it may be the better practical option when coverage or tolerability favors semaglutide.

For ingredient-level detail, read semaglutide vs tirzepatide.

Quick Comparison

Question	Zepbound	Wegovy
Active ingredient	Tirzepatide	Semaglutide
Mechanism	Dual GIP / GLP-1 receptor agonist	GLP-1 receptor agonist
Weight-loss label	Chronic weight management	Chronic weight management
Average weight-loss edge	Usually higher	Strong, but lower than Zepbound in head-to-head data
Other label strengths	Includes obstructive sleep apnea in adults with obesity	Includes cardiovascular risk reduction in adults with overweight or obesity and established CVD

Head-to-Head Weight Loss

SURMOUNT-5 is the key study because it directly compared tirzepatide with semaglutide in adults with obesity or overweight.

Trial point	Zepbound / tirzepatide	Wegovy / semaglutide	Meaning
SURMOUNT-5 average weight loss	About 20.2%	About 13.7%	Zepbound had the clear average advantage.
Mechanism explanation	Two incretin pathways: GIP and GLP-1	One incretin pathway: GLP-1	The extra GIP activity may help explain larger average results.
Individual response	Can still vary widely	Can still work very well for many people	Trial averages are not personal guarantees.

Safety and Side Effects

Both products commonly cause gastrointestinal side effects, especially during dose escalation:

• Nausea.
• Vomiting.
• Diarrhea.
• Constipation.
• Reflux or abdominal discomfort.
• Lower appetite than intended.

Both labels also include warnings that require clinician screening. Read the product label and GLP-1 side effects before turning an efficacy comparison into a medication choice.

Which One Fits Which Search?

Scenario	Often points toward	Reason
Maximum average weight loss	Zepbound	Head-to-head data favor tirzepatide.
Established cardiovascular disease plus overweight or obesity	Wegovy	Wegovy has a cardiovascular risk-reduction label in this setting.
Obstructive sleep apnea with obesity	Zepbound	Zepbound has an OSA-related obesity label.
Insurance covers one but not the other	The covered product	Access often beats theoretical ranking.
One product causes intolerable GI effects	Try clinician-guided titration or switching	The best drug on paper is not useful if it cannot be tolerated.

Bottom Line

Zepbound is usually the stronger weight-loss choice on average. Wegovy remains a major option because semaglutide has broad clinical data, specific label strengths and sometimes better access. The best answer is the one a prescriber can match to the patient's risk profile, indication and coverage.

FAQ

Is Zepbound better than Wegovy?

For average weight loss, Zepbound generally performs better. Wegovy may still be preferred for specific label indications, coverage or tolerability.

What is the active ingredient in Zepbound?

Zepbound contains tirzepatide, a dual GIP/GLP-1 receptor agonist.

What is the active ingredient in Wegovy?

Wegovy contains semaglutide, a GLP-1 receptor agonist.

Did Zepbound and Wegovy have a head-to-head trial?

Yes. SURMOUNT-5 directly compared tirzepatide with semaglutide in adults with obesity or overweight and found greater average weight loss with tirzepatide.

Can you switch from Wegovy to Zepbound?

People do switch, but the transition should be managed by a prescriber because doses are not equivalent and GI side effects matter.

References

1. Aronne LJ, et al. Tirzepatide as compared with semaglutide for the treatment of obesity. New England Journal of Medicine.

2. Eli Lilly. Zepbound prescribing information.

3. Novo Nordisk. Wegovy prescribing information.

4. FDA. FDA approval announcement for Zepbound in chronic weight management.